Last reviewed · How we verify
copolymer 1
Copolymer 1 is a synthetic polymer that works by inducing an immune response against the myelin basic protein, thereby reducing inflammation in the central nervous system.
Copolymer 1 is a synthetic polymer that works by inducing an immune response against the myelin basic protein, thereby reducing inflammation in the central nervous system. Used for Relapsing-remitting multiple sclerosis.
At a glance
| Generic name | copolymer 1 |
|---|---|
| Sponsor | National Center for Research Resources (NCRR) |
| Drug class | Immunomodulator |
| Target | Myelin basic protein |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Copolymer 1 is a type of immunomodulatory therapy that has been shown to be effective in reducing the frequency of exacerbations in patients with multiple sclerosis. It works by inducing an immune response against the myelin basic protein, which is a key component of the myelin sheath that surrounds nerve fibers in the central nervous system. This immune response helps to reduce inflammation and damage to the myelin sheath, thereby slowing the progression of the disease.
Approved indications
- Relapsing-remitting multiple sclerosis
Common side effects
- Injection site reaction
- Fatigue
- Headache
- Nausea
- Dizziness
Key clinical trials
- Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis (NA)
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (NA)
- Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation (NA)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |